Dr. Reddy’s Receives Two USFDA Observations

Dr. Reddy’s Laboratories

Laboratories has received two observations in a USFDA Form 483 following a Pre-Approval Inspection (PAI) at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. USFDA Inspection Details The inspection was conducted from October 5 to October 7, 2026. Following the inspection, the US Food and Drug Administration issued Form 483 containing two observations. - Facility: FTO-11 manufacturing unit - Location: Pydibhimavaram, Andhra Pradesh - Inspection type: Pre-Approval Inspection (PAI) - Observations: 2 - Company response: Dr. Reddy’s said it will address the observations within the stipulated timeline. What Does Form 483 Mean? - A Form 483 records conditions that USFDA investigators believe may violate regulatory requirements. Receiving observations does not automatically mean that a facility has been declared non-compliant or that manufacturing has been suspended. - The company has not disclosed the specific nature of the two observations in its regulatory filing. - Their implications will depend on the issues identified and the company's response. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their risk profile before making any investment decision.